Test Bank For Clayton's Basic Pharmacology for Nurses 19th Edition By Michelle J. Willihnganz, Samuel L. Gurevitz, Bruce Clayton Chapter 1-48.

TestQBankQForQClayton’sQBasicQPharmacologyQforQNursesQ19thQEditi 1
on



COMPELETE TESTBANK Q




TESTBANK FOR CLAYON’S BASIC PHARMACOLOGY F
Q Q Q Q Q


OR NURSES 19TH EDITION/ WILLIHNGANZ VERIFIEDQ
Q Q Q Q Q Q


UESTIONS AND ANSWERS WITH 2024 UPDATES (ALLC
Q Q Q Q Q Q Q


HAPTERS INLUDED 1-48) Q Q

,TestQBankQForQClayton’sQBasicQPharmacologyQforQNursesQ19thQEditi 2
on




Chapter 01: Drug Definitions, Standards, and Information Sources
Q Q Q Q Q Q Q

QWillihnganz: Clayton’s Basic Pharmacology for Nurses, 19th Editi
Q Q Q Q Q Q Q

on


1. WhichQnameQidentifiesQaQdrugQlistedQbyQtheQUSQFoodQDru
gQAdministrationQ(FDA)?
a. Bran
b. Nonproprietar
c. Official
d. Trademark
ANS:
TheQofficialQnameQisQtheQnameQunderQwhichQaQdrugQisQlistedQby
QtheQ FDA.Q TheQ brandQ name,Q orQ trademark,Q isQ theQ nameQ givenQ

toQaQdrugQbyQitsQmanufacturer.QTheQnonproprietary,QorQgeneric,Q
nameQisQprovidedQbyQtheQUnitedQStatesQAdoptedQNamesQCoun
cil.
CognitiveQLevel:QKnowledge REF:Q p.Q9
OBJ:Q1NAT:QNCLEXQClientQNeedsQCategory:QSafe,QEffectiveQCa
reQEnvironmentQTOP:Q NursingQProcessQStep:QAssessment
CON:Q
PatientQEducation




2. WhichQsourceQcontainsQinformationQspecificQtoQnutritionalQsupplements?
a. USPQDictionaryQofQUSANQ &QInternationalQDrugQNames
b. NaturalQMedicinesQComprehensiveQDatabase
c. UnitedQStatesQPharmacopoeia/NationalQFormularyQ(USPQNF)
d. DrugQInteractionQFacts
ANS:Q C
UnitedQStatesQPharmacopoeia/NationalQFormularyQcontainsQinformationQspecificQtoQnutrition
alQsupplements.QUSPQDictionaryQofQUSANQ&QInternationalQDrugQNamesQisQaQcompilationQofQ
drugQnames,QpronunciationQguide,QandQpossibleQfutureQFDAQapprovedQdrugs;QitQdoesQnotQinclu
deQnutritionalQsupplements.QNaturalQMedicinesQComprehensiveQDatabaseQcontains
evidence-
basedQinformationQonQherbalQmedicinesQandQherbalQcombinationQproducts;QitQdoesQnotQincludeQi
nformationQspecificQtoQnutritionalQsupplements.QDrugQInteractionQFactsQcontainsQcomprehens
iveQinformationQonQdrugQinteractionQfacts;QitQdoesQnotQincludeQnutritionalQsupplements.

DIF: CognitiveQLevel:QKnowledge REF:Q p.Q4
OBJ:Q3QNAT:Q NCLEXQClientQNeedsQCategory:QPhysiologicalQInte
grity
TOP:Q NursingQProcessQStep:QAssessment CON:Q NutritionQ|QPatientQEducation

3. WhichQdrugQreferenceQcontainsQdrugQmonographsQthatQdescribeQallQdrugsQinQaQtherapeuticQclass?
a. DrugQFactsQandQComparisons

,TestQBankQForQClayton’sQBasicQPharmacologyQforQNursesQ19thQEditi 3
on
b. DrugQInteractionQFacts
c. HandbookQonQInjectableQDrugs
d. Martindale—TheQCompleteQDrugQReference

ANS:Q A
DrugQFactsQandQComparisonsQcontainsQdrugQmonographsQthatQdescribeQallQdrugsQinQaQ
therapeuticQclass.QMonographsQareQformattedQasQtablesQtoQallowQcomparisonQofQsimilarQ
products,QbrandQnames,Qmanufacturers,QcostQindices,QandQavailableQdosageQformsQOnl
ineQversionQisQavailable.

DIF: CognitiveQLevel:QKnowledge REF:Q p.Q4QTableQ1.2
OBJ:QQQ 3 NAT:Q NCLEXQClientQNeedsQCategory:QPhysiologicalQIntegrity
TOP:Q NursingQProcessQStep:QAssessment CON:Q SafetyQ|QPatientQEducationQ|QClinicalQJudgment

4. WhichQdrugQreferenceQcontainsQmonographsQaboutQvirtuallyQeveryQsingle-
entityQdrugQavailableQinQtheQUnitedQStatesQandQdescribesQtherapeuticQusesQofQdrugs,Qincluding
QapprovedQandQunapprovedQuses?

a. Martindale:QTheQCompleteQDrugQReference
b. AHFSQDrugQInformation
c. DrugQReference
d. DrugQFactsQandQComparisons
ANS:Q B
AHFSQDrugQInformationQcontainsQmonographsQaboutQvirtuallyQeveryQsingle-
entityQdrugQavailableQinQtheQUnitedQStatesQandQdescribesQtherapeuticQusesQofQdrugs,QincludingQa
pprovedQandQunapprovedQuses.

DIF: CognitiveQLevel:QKnowledge REF:Q p.Q4QTableQ1.2
OBJ:QQQ 3 NAT:Q NCLEXQClientQNeedsQCategory:QPhysiologicalQIntegrity
TOP:Q NursingQProcessQStep:QPlanning CON:Q SafetyQ|QPatientQEducationQ|QClinicalQJudgment

5. WhichQonlineQdrugQreferenceQmakesQavailableQtoQhealthcareQprovidersQandQtheQpublicQaQst
andard,Qcomprehensive,Qup-to-dateQlookQupQandQdownloadableQresourceQaboutQmedicines?
a. AmericanQDrugQIndex
b. AmericanQHospitalQFormulary
c. DailyMed
d. DrugQReference
ANS:Q C
DailyMedQmakesQavailableQtoQhealthcareQprovidersQandQtheQpublicQaQstandard,Qcomprehensiv
e,Qup-to-
dateQlookQupQandQdownloadableQresourceQaboutQmedicines.QTheQAmericanQDrugQIndexQisQnotQ
appropriateQforQpatientQuse.QTheQAmericanQHospitalQFormularyQisQnotQappropriateQforQpatien
tQuse.QTheQdrugQreferenceQisQnotQappropriateQforQpatientQuse.

DIF: CognitiveQLevel:QKnowledge REF:Q p.Q3Q|Qp.Q4
OBJ:Q3QNAT:Q NCLEXQClientQNeedsQCategory:QPhysiologicalQInte
grity
TOP:Q NursingQProcessQStep:QImplementation
CON:Q SafetyQ|QPatientQEducationQ|QClinicalQJudgment

6. WhichQlegislationQauthorizesQtheQFDAQtoQdetermineQtheQsafetyQofQaQdrugQbeforeQitsQmarketing?
a. FederalQFood,QDrug,QandQCosmeticQActQ(1938)
b. DurhamQHumphreyQAmendmentQ(1952)

, TestQBankQForQClayton’sQBasicQPharmacologyQforQNursesQ19thQEditi 4
on
c. ControlledQSubstancesQActQ(1970)
d. KefauverQHarrisQDrugQAmendmentQ(1962)
ANS:Q A
TheQFederalQFood,QDrug,QandQCosmeticQActQofQ1938QauthorizedQtheQFDAQtoQdetermineQtheQsa
fetyQofQallQdrugsQbeforeQmarketing.QLaterQamendmentsQandQactsQhelpedQtightenQFDAQcontrolQ
andQensureQdrugQsafety.QTheQDurhamQHumphreyQAmendmentQdefinesQtheQkindsQofQdrugsQthat
QcannotQbeQusedQsafelyQwithoutQmedicalQsupervisionQandQrestrictsQtheirQsaleQtoQprescriptionQby

QaQlicensedQpractitioner.QTheQControlledQSubstances QActQaddressesQonlyQcontrolledQsubstancesQ

andQtheirQcategorization.QTheQKefauverQHarrisQDrugQAmendmentQensuresQdrugQefficacyQandQgr
eaterQdrugQsafety.QDrugQmanufacturersQareQrequiredQtoQproveQtoQtheQFDAQtheQeffectivenessQofQ
theirQproductsQbeforeQmarketingQthem.

DIF: CognitiveQLevel:QKnowledge REF:Qp.Q5QTableQl.3
OBJ:Q 5
NAT:QNCLEXQClientQNeedsQCategory:QPhysiologicalQIntegrit
yQTOP:Q NursingQProcessQStep:QAssessment
CON:Q SafetyQ|QPatientQEducationQ|QEvidenceQ|QHealthQCareQLaw

7. WhichQclassificationQdoesQmeperidineQ(Demerol)QfallQunder?
a. I
b. II
c. III
d. IV
ANS:Q B
MeperidineQ(Demerol)QisQaQScheduleQIIQdrug;QitQhasQaQhighQpotentialQforQabuseQandQmayQleadQ
toQsevereQpsychologicalQandQphysicalQdependence.QScheduleQIQdrugsQhaveQhighQpotentialQforQab
useQandQnoQrecognizedQmedicalQuse.QScheduleQIIIQdrugsQhaveQsomeQpotentialQforQabuse.QUseQ
mayQleadQtoQlowQtoQmoderateQphysicalQdependenceQorQhighQpsychologicalQdependence.QSched
uleQIVQdrugsQhaveQlowQpotentialQforQabuse.QUseQmayQleadQtoQlimitedQphysicalQorQpsychologica
lQdependence.

DIF: CognitiveQLevel:QKnowledge REF:Q p.Q10
OBJ:Q2QNAT:Q NCLEXQClientQNeedsQCategory:QSafe,QEffectiveQCa
reQEnvironment
TOP:Q NursingQProcessQStep:QAssessment CON:Q PatientQEducationQ|QAddictionQ|QPain

8. WhichQactionQwouldQtheQFDAQtakeQtoQexpediteQdrugQdevelopmentQandQapprovalQforQanQoutbre
akQofQsmallpox?
a. ListQsmallpoxQasQaQhealthQorphanQdisease.
b. OmitQtheQpreclinicalQresearchQphase.
c. ExtendQtheQclinicalQresearchQphase.
d. FastQtrackQtheQinvestigationalQdrug.
ANS:Q D
OnceQtheQInvestigationalQNewQDrugQApplicationQhasQbeenQapproved,QtheQdrugQcanQreceiveQhi
ghestQpriorityQwithinQtheQagency,QwhichQisQcalledQfastQtracking.QAQsmallpoxQoutbreakQwouldQ
becomeQaQpriorityQconcernQinQtheQworld.QOrphanQdiseasesQareQnotQresearchedQinQaQpriorityQma
nner.QPreclinicalQresearchQisQnotQomitted.QExtendingQanyQphaseQofQtheQresearchQwouldQmeanQa
QlongerQtimeQtoQdevelopQaQvaccine.QTheQFDAQmustQensureQthatQallQphasesQofQtheQpreclinicalQan

dQclinicalQresearchQphaseQhaveQbeenQcompletedQinQaQsafeQmanner.

DIF: CognitiveQLevel:QKnowledge REF:Q p.Q7 OBJ:Q 5